0001104659-24-023870.txt : 20240214
0001104659-24-023870.hdr.sgml : 20240214
20240214165049
ACCESSION NUMBER: 0001104659-24-023870
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20240214
DATE AS OF CHANGE: 20240214
EFFECTIVENESS DATE: 20240214
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001017491
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 870449967
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-505332
FILM NUMBER: 24639779
BUSINESS ADDRESS:
STREET 1: 300 PARK AVENUE
STREET 2: 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (646) 293-2100
MAIL ADDRESS:
STREET 1: 300 PARK AVENUE
STREET 2: 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
FORMER COMPANY:
FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC.
DATE OF NAME CHANGE: 20100914
FORMER COMPANY:
FORMER CONFORMED NAME: NEXMED INC
DATE OF NAME CHANGE: 19970311
D
1
primary_doc.xml
X0708
D
LIVE
0001017491
SEELOS THERAPEUTICS, INC.
300 PARK AVENUE
2ND FLOOR
NEW YORK
NY
NEW YORK
10022
(646) 293-2100
NEVADA
None
APRICUS BIOSCIENCES, INC.
NEXMED INC
Corporation
true
Raj
Mehra
c/o Seelos Therapeutics, Inc.
300 Park Avenue, 2nd Floor
New York
NY
NEW YORK
10022
Executive Officer
Director
Brian
Lian
c/o Seelos Therapeutics, Inc.
300 Park Avenue, 2nd Floor
New York
NY
NEW YORK
10022
Director
Richard
W.
Pascoe
c/o Seelos Therapeutics, Inc.
300 Park Avenue, 2nd Floor
New York
NY
NEW YORK
10022
Director
Daniel
J.
O'Connor
c/o Seelos Therapeutics, Inc.
300 Park Avenue, 2nd Floor
New York
NY
NEW YORK
10022
Director
Margaret
Dalesandro
c/o Seelos Therapeutics, Inc.
300 Park Avenue, 2nd Floor
New York
NY
NEW YORK
10022
Director
Michael
Golembiewski
c/o Seelos Therapeutics, Inc.
300 Park Avenue, 2nd Floor
New York
NY
NEW YORK
10022
Executive Officer
Biotechnology
No Revenues
- 06b
false
2024-01-30
false
true
true
false
0
A.G.P./Alliance Global Partners
8361
None
None
590 MADISON AVENUE, 28TH FOOR
NEW YORK
NY
NEW YORK
10022
NJ
NEW JERSEY
NY
NEW YORK
false
3574468
0
3574468
Represents the aggregate exercise price of warrants to purchase 3,404,256 shares of the Company's common stock, which were issued in connection with an offering of 3,404,256 shares of the Company's common stock issued in a registered direct offering.
false
3
280000
65000
$280.000.00 is for a fee of 7.0% of the gross proceeds from the sale of securities in the registered direct offering and concurrent private placement of warrants, and up to $65,000 is for the reimbursement of expenses incurred by the placement agent.
0
false
SEELOS THERAPEUTICS, INC.
/s/ Michael Golembiewski
Michael Golembiewski
Chief Financial Officer
2024-02-14